FAQ on Branded Legacy, Inc.'s Acquisition of Bio-Legacy Evaluative Group and Expansion into Intranasal Drug Delivery

What is the significance of Branded Legacy’s acquisition of Bio-Legacy Evaluative Group?

The acquisition signifies Branded Legacy’s strategic entry into high-growth markets for addiction treatments and vaccine accessibility through advanced intranasal drug delivery technologies, leveraging Bio-Legacy’s patented naloxone device.

How much is the proposed transaction for the acquisition?

The proposed transaction is valued at $1.5 million in Preferred D stock, transferring 100% of Bio-Legacy’s equity, assets, and IP to Branded Legacy.

Who will lead Branded Legacy after the acquisition?

Following the closing, Bio-Legacy CEO Amin Janmohamed will assume the roles of CEO and Chairman of Branded Legacy.

What are the expected timelines for manufacturing and market readiness of the naloxone device?

Manufacturing prototyping is targeted for Q3 2025, with market readiness for the naloxone device expected by Q1 2027.

What market size is projected for the naloxone device by 2032?

The market for the naloxone device is projected to exceed $1.16 billion by 2032.

Where can I find more information about Branded Legacy?

More information about Branded Legacy can be found on their website at https://BrandedLegacy.com.

Where can I view the full press release about this acquisition?

The full press release can be viewed at https://ibn.fm/5kuAK.

What is Branded Legacy’s focus as a company?

Branded Legacy specializes in the development and commercialization of biotech and wellness products, focusing on strategic growth, innovation, and quality to enhance lives and create sustainable value for its shareholders.